No changes here, showing a substantial pull back so looking for a support shortly, holding for Wave 2 and Wave 3 is likely next. I like this company and what they are doing, I will leave a company description below:
'CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.'
TommyJR
2023-02-22 11:35:20 +0000 UTC